5% af de patienter, som får abacavir (som også er det aktive indholdsstof i Ziagen), en overfølsomhedsreaktion.
In clinical studies approximately 5% of subjects receiving abacavir (which is also the active substance of Ziagen) develop a hypersensitivity reaction.